NeuBase board does not believe special dividend will enhance shareholder value

NeuBase Therapeutics issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation and their subsequent press release issued on September 6, 2023. “The NeuBase Board of Directors appreciates input from its shareholders. The Board remains committed to completing its comprehensive exploration of strategic alternatives focused on maximizing shareholder value. The Board does not believe that shareholder value will be enhanced by issuing the special $1 per share dividend Symetryx requested in their press release. The Board and management will continue to seek an open and active dialogue with its shareholders, including Symetryx.”